

# APPLICATION FOR LICENSE TO EXPORT NUCLEAR MATERIAL AND EQUIPMENT

(See Instructions on Reverse)

Estimated burden per response to comply with this mandatory collection request: 2.4 hours. This submittal is reviewed to ensure that the applicable statutory, regulatory, and policy considerations are satisfied. Send comments regarding burden estimate to the Records Management Branch (T-6 E6), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by internet e-mail to [infocollects@nrc.gov](mailto:infocollects@nrc.gov), and to the Desk Officer, Office of Information and Regulatory Affairs, NEOB-10202, (3150-0027), Office of Management and Budget, Washington, DC 20503. If a means used to impose an information collection does not display a currently valid OMB control number, the NRC may not conduct or sponsor, and a person is not required to respond to, the information collection.

1. APPLICANT'S USE		a. DATE OF APPLICATION 01/03/06		b. APPLICANT'S REFERENCE		2. NRC USE		a. DOCKET NUMBER		b. LICENSE NUMBER CBP0030			
3. APPLICANT'S NAME AND ADDRESS						4. SUPPLIER'S NAME AND ADDRESS (Complete if applicant is not supplier)							
a. NAME Community Blood Center						a. NAME							
b. STREET ADDRESS (Facility Site) 349 South Main Street						b. STREET ADDRESS							
c. CITY Dayton			d. STATE Ohio		e. ZIP CODE 45402		c. CITY			e. ZIP CODE			
f. TELEPHONE NUMBER (937) 461-3450		g. FAX (937) 461-9972		h. E-MAIL kpaulick@cbccs		c. CITY			e. ZIP CODE				
5. FIRST SHIPMENT SCHEDULED		6. FINAL SHIPMENT SCHEDULED		7. APPLICANT'S CONTRACTUAL DELIVERY DATE		8. PROPOSED LICENSE EXPIRATION DATE 12/31/2006		9. CONTRACT NO.					
10. ULTIMATE FOREIGN CONSIGNEE						11. ULTIMATE END USE (Include plant or facility name) MDS Nordion manufactures and distributes sealed sources and devices and will accept return sources from customers for inspection, disposal, recycling, or reuse.							
a. NAME MDS Nordion						11a. DATE REQUIRED							
b. STREET ADDRESS (Facility Site) 447 March Road						13. INTERMEDIATE END USE Not applicable							
c. CITY Ottawa, Ontario			d. COUNTRY Canada			13a. DATE REQUIRED							
12. INTERMEDIATE FOREIGN CONSIGNEE						15. INTERMEDIATE END USE Not applicable							
a. NAME Not applicable						15a. DATE REQUIRED							
b. STREET ADDRESS (Facility Site)													
c. CITY			d. COUNTRY										
14. INTERMEDIATE FOREIGN CONSIGNEE													
a. NAME Not applicable													
b. STREET ADDRESS (Facility Site)													
c. CITY			d. COUNTRY										
16. COM CODE		17. DESCRIPTION (Include chemical and physical form of nuclear material; give dollar value of nuclear equipment and components)				18. MAX. ELEMENT WEIGHT		19. MAX. WT. %		20. MAX. ISOTOPE WEIGHT		21. UNIT	
		Return Gammacell 1000 S/N 20 Model B to MDS Nordion Cesium 137 Chemical Form: Element Physical Form: Solid				N/A		N/A				Ci	
22. FOREIGN OBLIGATIONS BY COUNTRY AND PERCENTAGE (Use separate sheet if necessary) Not applicable													
23. ADDITIONAL INFORMATION ON CONSIGNEES, END USES, AND PRODUCT DESCRIPTION (Use separate sheet if necessary) Please find attached MDS Nordion facility license which is valid until October 31, 2015 and allows the possession of Cesium 137.													
24. The applicant certifies that this application is prepared in conformity with Title 10, Code of Federal Regulations; and that all information in this application is correct to the best of his/her knowledge.													
25. AUTHORIZED OFFICIAL		a. SIGNATURE Kathy Paulick				b. TITLE Radiation Safety Officer							

RECEIVED DIP  
206 JAN 25 PM 1:41



Community Blood Center  
Community Tissue Services

www.cbccts.org

ISO 9001-2000 Registered

**MAIN OFFICE**

349 South Main St.  
Dayton, Ohio 45402-2715  
1-800-388-4483  
(937) 461-3450  
FAX (937) 461-9217

**BLOOD CENTERS**

105 South D St.  
Hamilton, Ohio 45013  
(513) 894-6966  
FAX (513) 894-4901  
3990 Roosevelt Blvd. Suite C  
Middletown, Ohio 45044  
(513) 727-1995  
FAX (513) 727-0006

4821 Old National Rd. East  
Richmond, Indiana 47374  
(765) 962-6329  
FAX (765) 966-3957

2200 North Limestone St.  
Suite 106  
Springfield, Ohio 45503  
(937) 399-2611  
FAX (937) 399-5044

**TISSUE CENTERS**

349 South Main St.  
Dayton, Ohio 45402-2715  
1-800-684-7783  
(937) 222-0228  
FAX/OFFICE (937) 461-4225  
FAX/DIST. (937) 461-4237

328 S. Adams Street  
Fort Worth, Texas 76104  
1-800-905-2556  
(817) 332-1898  
FAX (817) 332-1958

3425 North First St., Suite 103  
Fresno, California 93726  
1-800-201-8477  
(559) 224-1168  
FAX (559) 229-7217

7770 E. 88th Street  
Indianapolis, Indiana 46256  
1-800-984-7783  
(317) 842-0009  
FAX (317) 842-0243

16361 N.E. Cameron Blvd.  
Portland, Oregon 97230  
1-800-545-8668  
(503) 408-9394  
FAX (503) 408-9395

2736 N. Holland-Sylvania Rd.  
Toledo, Ohio 43615  
1-866-684-7783  
(419) 536-4924  
FAX (419) 536-4973

7821 Bartram Ave., Suite E  
Philadelphia, PA 19153  
1-800-456-5445  
(215) 937-9662  
FAX (215) 937-9858

January 13, 2006

Ms. Margaret M. Doane  
Deputy Director  
Office of International Programs  
U.S. Nuclear Regulatory Commission  
Washington, DC 20555-0001

Dear Ms. Doane,

Enclosed is the application fee and information required in the application letter for a specific license, including NRC Form 7, as required in the Code of Federal Regulations part 110.32.

The Community Blood Center, under license by the Ohio Department of Health, currently operates a Gammacell 1000, a sealed source blood product irradiator manufactured by MDS Nordion. The Community Blood Center recently purchased a Gammacell 3000 from MDS Nordion and anticipates delivery of the new unit in May 2006. Upon delivery of the Gammacell 3000, MDS Nordion will take possession of the Gammacell 1000 for return to the manufacturer for recycling or disposal.

An application for an amendment to Community Blood Center's radioactive materials license was granted by the Ohio Department of Health and the 4<sup>th</sup> amendment to the license was issued 11/10/05 allowing for possession of both the Gammacell 1000 and Gammacell 3000 (see enclosed copy).

On 11/23/05, the Ohio Department of Health issued amendment 5 addressing the Increased Controls for Licensees that Possess Sources Containing Radioactive Material Quantities of Concern (see enclosed copy). The Community Blood Center will be in compliance with the increased control measures within the required timeframe and prior to delivery of the Gammacell 3000.

Should you require additional information please contact me at the number below.

Sincerely,  
*Kathy Paulick*  
Kathy Paulick, RSO  
Community Blood Center  
937-461-3593

### **110.32 Information required in an application for a specific license/NRC Form 7.**

(a) Name and address of applicant.

(b) Name and address of supplier of equipment or material.

(c) Country of origin of equipment or material, and any other countries that have processed the material prior to its import into the U.S.

(Note: This is meant to include all obligations attached to the material, according to the definition of obligations in § 110.2. Licensees must keep records of obligations attached to material which they own or is in their possession.)

(d) Names and addresses of all intermediate and ultimate consignees, other than intermediate consignees performing shipping services only.

(e) Dates of proposed first and last shipments.

(f) Description of the equipment or material including, as appropriate, the following:

(1) Maximum quantity of material in grams or kilograms (terabequerels or TBq for byproduct material) and its chemical and physical form.

(2) For enriched uranium, the maximum weight percentage of enrichment and maximum weight of contained U-235.

(3) For nuclear equipment, total dollar value.

(4) For nuclear reactors, the name of the facility and its design power level.

(5) For proposed exports or imports of radioactive waste, and for proposed exports of incidental radioactive material--the volume, classification (as defined in § 61.55 of this chapter), physical and chemical characteristics, route of transit of shipment, and ultimate disposition (including forms of management) of the waste.

(6) For proposed imports of radioactive waste--the industrial or other process responsible for generation of the waste, and the status of the arrangements for disposition, e.g., any agreement by a low-level waste compact or State to accept the material for management purposes or disposal.

(7) Description of end use by all consignees in sufficient detail to permit accurate evaluation of the justification for the proposed export or import, including the need for shipment by the dates specified.

(g) For proposed imports of material listed in Table 1 of Appendix P to this part, a copy of the applicant's authorization to receive and possess the radioactive material to be imported for each recipient.

(h) For proposed exports of material listed in Table 1 of Appendix P to this part, pertinent documentation that the recipient of the material has the necessary authorization under the

laws and regulations of the importing country to receive and possess the material. Pertinent documentation shall consist of a copy of the recipient's authorization to receive and possess the material to be exported or a confirmation from the government of the importing country that the recipient is so authorized. The recipient authorization shall include the following information:

- (1) Name of the recipient
- (2) Recipient location and legal address or principal place of business
- (3) Relevant radionuclides and radioactivity being imported or that the recipient is authorized to receive and possess
- (4) Uses, if appropriate
- (5) The expiration date of the recipient's authorization (if any)

[49 FR 47200, Dec. 3, 1984, as amended at 58 FR 13004, Mar. 9, 1993. Redesignated at 59 FR 48998, Sept. 26, 1994; 60 FR 37564, July 21, 1995; 65 FR 70291, Nov. 22, 2000; 70 FR 37992, July 1, 2005]

Community Blood Center  
Community Tissue Services  
Dayton, Ohio 45402

**I. 110.32 Information required in an application for a specific license \_ Import**

- (a) Community Blood Center  
Community Tissue Services  
349 South Main Street  
Dayton, Ohio 45402
- (b) MDS Nordion  
447 March Road  
Ottawa, Ontario  
Canada, K2K 1XB
- (c) The Gammacell 3000 is manufactured in Canada.
- (d) The Gammacell 3000 will be transported by truck from MDS Nordion,  
447 March Road, Ottawa, Ontario K2K 1X8 to the Community Blood Center,  
349 South Main Street, Dayton, Ohio 45402.
- (e) The Gammacell 3000 will be shipped to the Community Blood Center  
on or about [REDACTED]
- (f) The Gammacell 3000 is a self shielded blood product irradiator.
  - (1) The Gammacell 3000's source is  
Cesium 137  
Maximum activity [REDACTED]  
Chemical Form: Element  
Physical Form: Solid
  - (2-6) Not applicable
  - (7) The Gammacell 3000 will be used by the Community Blood Center to  
deliver a controlled dose of radiation to blood products for medical  
purposes. The shipment of the Gammacell 3000 will be accomplished  
in coordination with the return of the Gammacell 1000 on or around  
[REDACTED]
- (g) A copy of the Community Blood Center's current radioactive materials  
license is enclosed.
- (h) N/A

Community Blood Center  
Community Tissue Services  
Dayton, Ohio 45402

**II. 110.32 Information required in an application for a specific license/NRC Form 7\_Export**

(a)

Community Blood Center  
Community Tissue Services  
349 South Main Street  
Dayton, Ohio 45402

(b)

Community Blood Center  
Community Tissue Services  
349 South Main Street  
Dayton, Ohio 45402

(c)

The Gammacell 1000 S/N 20 was manufactured in Canada.

(d)

MDS Nordion will take possession of the Gammacell 1000 and the unit will be shipped by truck from the Community Blood Center, 349 South Main Street, Dayton, Ohio 45402 to MDS Nordion, 447 March Road, Ottawa, Ontario, Canada, K2K 1X8.

(e)

The Gammacell 1000 will be shipped to MDS Nordion on or about [REDACTED]

(f)

The Gammacell 1000 is a self shielded blood product irradiator.

(1)

The Gammacell 1000's source is  
Cesium 137  
Maximum activity [REDACTED]  
Chemical Form: Element  
Physical Form: Solid

(2-6) Not applicable

(7)

MDS Nordion will accept the return of the Gammacell 1000 for disposal or recycling. The return of the Gammacell 1000 will be accomplished in coordination with the shipment of the Gammacell 3000 on or about May 15, 2006.

(g)

N/A

(h)

A copy of MDS Nordion's current radioactive materials license is enclosed.